HIV-1 reverse transcriptase: A potential target for marine products

Revista Brasileira de Farmacognosia

Volumn 22, Issue 4, 2012, Pages 881-888

  Miceli, Leonardo A ^a   de Souza, Alessandra M T ^b   Rodrigues, Carlos R ^b   Paixão, Izabel C N P ^a   Teixeira, Valéria L ^a   Castro, Helena C ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Brown algae; Diterpenes; HIV; Inhibitor; Natural products; Reverse transcriptase

Indexed keywords

6 ACETOXYDICHOTOMA 3,14 DIENE 1,17 DIAL; 6 ACETOXYDICHOTOMA 3,14 DIENO 1,17 DIAL; 6 HYDROXYDICHOTOMA 3,14 DIEN 1,17 DIAL; 6 HYDROXYDICHOTOMA 3,14 DIENE 1,17 DIAL; ABACAVIR; ADEFOVIR; ANTIVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; DITERPENE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LECTIN; NATURAL PRODUCT; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SESQUITERPENE DERIVATIVE; STAVUDINE; TERPENE; TERPENE DERIVATIVE; TRITERPENE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACIDEMIA; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ANTIVIRAL ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; DYSLIPIDEMIA; ERYTHEMA; ESOPHAGUS ULCER; FATTY LIVER; FEVER; GENE TARGETING; HALLUCINATION; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; INSOMNIA; LACTIC ACIDOSIS; LIPOATROPHY; LIVER FAILURE; MALAISE; MARINE SPECIES; MEDICAL LITERATURE; MULTIDRUG RESISTANCE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NIGHTMARE; NONHUMAN; PANCREATITIS; PATHOLOGY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; RASH; REVIEW; SEAWEED; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 84863993391     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2012005000084     Document Type: Review

References (63)

1. Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J 2006. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1-13.
2. Arts EJ, Le Grice SF 1995. Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. Progr Nucleic Acid Res Mol Biol 58: 339-393.
3. Ayehunie S, Belay A, Baba TW, Ruprecht RM 1998. Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis (Arthrospira platensis). J Acq Imm Deficl 18: 7-12.
4. Balzarini J 2004. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4: 921-944.
5. Barbosa JP, Pereira RC, Abrantes JL, Cirne-Santos CC, Rebello MA, Frugulhetti ICPP, Teixeira VL 2004. In vitro antiviral diterpenes from the Brazilian brown alga Dictyota pfaffii. Planta Med 70: 856-860.
6. Barbosa JP, Teixeira VL, Villa R, Pereira RC, Abrantes JL, Frugulhetti ICPP 2003. A dolabellane diterpene from the Brazilian brown alga Dictyota pfaffii. Biochem Syst Ecol 3: 1451-1453.
7. Barreca ML, Rao A, De Luca L, Zappalà M, Gurnari C, Monforte P, De Clercq E, Van Maele B, Debyser Z, Witvrouw M, Briggs JM, Chimirri A 2004. Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Model 44: 1450-1455.
8. Blanco J-L, Varghese V, Rhee S-Y, Gatell JM, Shafer RW 2011. HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications. J Infect Dis 31: 1204-1214.
9. Blunt J, Copp B, Munro M, Northcote P, Prinsep M 2006. Marine natural products RID D-3706-2009. Nat Prod Rep 23: 26-78.
10. Boyer PL, Ferris AL, Clark P, Whitmer J, Frank P, Tantillo C, Arnold E, Hughes SH 1994. mutational analysis of the fingers and palm subdomains of Human Immunodeficiency Virus Type-1 (HIV-1) reverse transcriptase. J Mol. Biol 243: 472-483.
11. Boyer PL, Tantillo C, Jacobo-Molina A, Nanni RG, Ding J, Arnold E, Hughes SH 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. PNAS 91: 4882-4886.
12. Brautigam CA, Steitz TA 1998. Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes. Curr Opin Struct Biol 8: 54-63.
13. Caffrey M 2011. HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol 19: 191-197.
14. Castro HC, Abreu PA, Geraldo RB, Martins RCA, dos Santos R, Loureiro NIV, Cabral LM, Rodrigues CR 2011. Looking at the proteases from a simple perspective. J Mol Recognit 24: 165-81.
15. Castro HC, Loureiro NIV, Pujol-Luz M, Souza AMT, Albuquerque MG, Santos DO, Cabral LM, Frugulhetti ICPP, Rodrigues CR 2006. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr Med Chem 13: 313-324.
16. CDC Centers for Disease Control and Prevention. 2008. Global HIV /AIDS. http://www.cdc.gov/hiv/resources/qa/index.htm, accessed Nov 2011.
17. Cihlar T, Ray AS 2010. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antivir Res 85: 39-58.
18. Cirne-Santos CC, Teixeira VL, Castello-Branco LR, Frugulhetti ICPP, Bou-Habib DC 2006. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the Brazilian algae Dictyota pfaffii. Planta Med 72: 295-299.
19. Cirne-Santos TM, Teixeira, VL, Fontes, CF, Rebello MA, Castello-Branco LR, Abreu CM., Tanuri A, Frugulhetti ICPP, Bou-Habib DC 2008. The dolabellane diterpene dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptae enzyme. Antivir Res 77:64-71.
20. Das K, Clark, Lewi PJ, Heeres J, de Jonge MR, Koymans LMH, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E 2004. Roles of conformational and positional adaptability in structurebased design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47:2550-2260.
21. De Clercq E 1998. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir Res 38: 153-179.
22. De Clercq E 2004. Anti-HIV chemotherapy: Current state of the art. Med Chem Res 13: 439-478.
23. De Paula JC, Vallim MA, Teixeira VL 2011. What are and where are the bioactive terpenoids metabolites from Dictyotaceae (Phaeophyceae)? Rev Bras Farmacogn 21: 216-28.
24. Debnath AK 2005. Application of 3D-QSAR techniques in anti- HIV-1 drug design - an overview. Curr Pharm Design 11: 3091-3110.
25. Ehteshami M, Goette M 2008. Effects of Mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. Aids Rev 10: 224-235.
26. Faulkner DJ 1992. Marine natural products. Nat Prod Rep 9: 323-364.
27. Girard MP, Osmanov S, Assossou OM, Kieny MP 2011. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 29: 6191-6218.
28. Harper MK, Bugni TS, Copp BR, James RD, Lindsay BS, Richardson AD, Schnabel PC, Tasdemir D, Vanwagoner RM, Verbitski SM, Ireland CM, 2001. Introduction to the chemical ecology of marine natural products. In: Mcclintock JB, Baker BJ (Eds.). Marine Chemistry Ecology. Boca Raton: C.R.C. Press, p. 3-69.
29. Kelecom A, Teixeira VL 1988. Dolastane diterpenes from the marine brown alga Dictyota cervicornis. Phytochemistry 27: 2907-2909.
30. Kim SK, Karadeniz F 2011. Anti-HIV Activity of extracts and compounds from marine algae. Adv Food Res 64: 255-265.
31. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexes with an inhibitor. Science 256: 1783-1790.
32. Martin JC, Hitchcock MJM, De Clercq E, Prusoff WH 2010. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. Antivir Res 85: 34-38.
33. Martinez-Picado J, Martínez MA 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Res 134: 104-123.
34. Menéndez-Arias L 2002. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends in Pharmacol Sci 23: 381-388.
35. Menéndez-Arias L, Betancor G, Matamoros T 2011. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antivir Res 92: 139-149.
36. Mechellou, Y, De Clercq E 2010. Twenty-six years of anti- HIV-1 drug discovery: where do we stand and where do we go? J Med Chem 53: 521-538
37. Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, Friedland GH, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM 2005.Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. Aids 19: 441-443.
38. Mulky A, Kappes JC 2005. Analysis of human immunodeficiency Virus Type 1 Reverse Transcriptase subunit structure/function in the context of infectious virions and human target cells. Antimicrob Agents Chemother 49: 3762-3769.
39. Paixão INPP, Teixeira VL, Cirne-Santos CC, Vallim MA, Cavalcanti DN, Castello-Branco LR, De-Paula JC 2010. Extrato, composição farmacêutica e processo de obtenção de substâncias que apresentam ação inibitória contra o vírus HIV-1. INPI register number 221007209660 in 10/22/2010.
40. Patel PH, Jacobo-Molina A, Ding J, Tantillo C, Clark AD Jr, Raag R, Nanni RG, Hughes SH, Arnold E 1995. Insights into DNA polymerization mechanisms from structure and function-analysis of HIV-1 reverse-transcriptase. Biochem 34: 5351-5363.
41. Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, Schellekens K, Janssen MAC, De Clercq E, Janssen PAJ 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470-474.
42. Pendri A, Meanwell NA, Peese KM, Walker MA 2011. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Exp Op Therap Patents 21: 1173-1189.
43. Pereira HS, Leão-Ferreira LR, Moussatché N, Teixeira VL, Cavalcanti DN, Costa LJ, Diaz R, Frugulhetti ICPP 2004. Antiviral activity of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis against human immunodeficiency virus type 1 (HIV-1). Antivir Res 64: 69-76.
44. Pereira HS, Leão-Ferreira LR, Moussatché N, Teixeira VL, Cavalcanti DN, Costa LJ, Diaz R, Frugulhetti ICPP 2005. Effects of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on HIV-1 reverse transcriptase. Planta Med 71: 1019-1024.
45. Pretorius E, Klinker H, Rosenkranz B 2011. The role of therapeutic drug monitoring in the management of patients with Human Immunodeficiency Virus Infection. Ther Drug Monit 33: 265-274.
46. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Monforte M, Monforte P, Pannecouque C, Zappalà M 2004. Synthesis of new 2,3-diaryl-1,3-thizolidin-4-ones as anti-HIV-1 agents. Il Farmaco 59: 33-39.
47. Rodgers DW, Gamblin SJ, Harris BA, Ray S, Culp JS, Hellmig B, Woolf DJ, Debouck C, Harrison SC 1995. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. PNAS 92: 1222-1226.
48. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 385: 693-713.
49. Shih CK, Rose JM, Hansen GL, Wu JC, Bacolla A, Griffin JA 1991. Chimeric human immunodeficiency virus type 1/ type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. PNAS 88: 9878-9882.
50. Silva TI, Cotton M, Rowland-Jones SL 2008. HIV-2: the forgotten AIDS virus. Trends Microbiol 16: 588-595.
51. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG 2010. Structural aspects of drug resistance and inhibition of HIV-1 Reverse Transcriptase Viruses 2: 606-638.
52. Sluis-Cremer N, Temiz NA, Bahar I 2004. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2: 323-332.
53. Sweeney ZK, Klumpp K 2008. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: The development pipeline and recent clinical data. Curr Opin Drug Disc 11: 458-470.
54. Teas J, Hebert JR, Fitton JH, Zimba PV 2004. Algae - A poor man's HAART? Med Hypotheses 62: 507-510.
55. Teixeira C, Gomes JRB, Gomes P, Maurel F 2011. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur J Med Chem 6: 979-992.
56. Teixeira VL, Tomassini T, Fleury BG, Kelecom A 1986a. Dolastane and secodolastane diterpenes from the brown alga, Dictyota cervicornis. J Nat Prod 49: 570-575.
57. Teixeira VL, Tomassini T, Kelecom A 1986b. Cervicol, a further secodolastane diterpene from the marine brown alga Dictyota cervicornis Kützing (Phaeophyceae, Dictyotaceae). Bull Soc Chim Belg 95: 263-268.
58. Temesgen Z, Warnke D, Kasten MJ 2006. Current status of antiretroviral therapy. Expert Opin Pharmaco 7: 1541-1554.
59. Vallim, MA, Barbosa JE, Cavalcanti DN, De-Paula JC, Silva VAGG, Teixeira VL, Paixão ICNP 2010. In vitro antiviral activity of diterpenes isolated from the Brazilian brown alga Canistrocarpus cervicornis. J Med Plants Res 4:2379-2382.
60. Vidotti EC, Rollemberg MDCE 2004. Algae: From aquatic environment economy to bioremediation and analytical chemistry. Quim Nova 27: 139-145.
61. Vo TS, Kim SK 2010. Potential Anti-HIV Agents from marine resources: an overview. Mar Drugs 8: 2871-2892.
62. WHO 2010. HIV/AIDS - Data and statistics. Global summary of the AIDS epidemic. http://www.who.int/hiv/data/en,accessed Nov 2011.
63. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X 2011. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev doi:10.1002/med.2022, 2011.